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INTRODUCTION
Dog remains the most important agent of 
transmission of rabies to humans in Africa and 
Asia (Warrell and Warrell 1988; CDC, 2009; 
Benka, 2009). The administration of human 
rabies immunoglobulin (HRIG) combined with 
post exposure vaccination can neutralize the 
virus before it invades the nervous system in the 
case of human victim thus effectively preventing 
clinical manifestation of rabies and death in man 
(Jackson et al., 2003). However, rabid dogs 
would continue to infect human population with 
the disease in its most virulent form because of 
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continuous circulation of the virus in susceptible 
population. This may result in diverse strains 
that can evade the immune systems of both man 
and animal. Thus, rabies, though a preventable 
zoonosis, is yet to be effectively controlled and 
its true impact is largely underestimated 
(Coleman et al., 2004). 
The importance of rabies control in dogs by 
vaccination cannot be overemphasised. This 
effective means of rabies prevention has 
however been hampered by inadequate 
resources, low public awareness, poor 
surveillance, inadequate research, poor dog 
vaccination coverage and poor compliance in 
resource poor countries. With an estimated 
55,000 human deaths reported annually, mainly 
in Africa and Asia, rabies control demands more 
seriousness of an emergency disease on the part 
of policy makers and researchers (Knobel et al., 
2005; CDC, 2009) 
Nigerian Governments at all levels and Non-
Governmental Organisations have made 
immense contributions through the annual anti-
rabies vaccination campaigns in dogs and cats. 
Such State and Local Government Authorities 
mostly procure anti-rabies vaccines which are 
administered either at a subsidized rate or free of 
charge to dogs within their localities. These 
vaccines are often sourced directly from 
National Veterinary Research Institute (NVRI), 
Vom (the only veterinary vaccine producing 
institution in the country) and distributed 
through a chain until they get to the field. 
However, these networks of distribution do not 
always ensure the maintenance of cold chain. 
Thus the immunogenicity/viability of the 
vaccines at the point of use cannot be 
guaranteed. Following complaint from the field, 
this study was carried out to re-assess the 
viability of rabies vaccine sourced from NVRI 
Vom.
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Two vials of anti-rabies vaccine produced by 
NVRI (Batch 04/2008) and procured by 
Shelleng Local Government Area of Adamawa 
state were received by the Quality Control 
Division, NVRI, Vom with a request for re-
evaluation. The vaccines had been with the 
client for about 4 months prior to submission. 
Handling of these vaccines was believed to have 
been compromised in the field, and the authority 
wished to revalidate its potency before being 
issued for anti rabies campaign in the Local 
Government Area. These vaccines were tested 
alongside the reference samples of the same 
production batch.
Laboratory Animals
One hundred and twenty white albino mice (3-4 
weeks old) were obtained from the Small Animal 
Experimental Unit, Central Diagnostic Division, 
NVRI, Vom and 96 of these were assigned to 
groups of 8 each (F1-F5 for the field originated; 
R1-R5 for the reference vaccines and C1&C2 for 
negative controls). The mice were given 
pelletized feed and water ad libitum and allowed 
to stabilize for 24 hours before being used.
Sample Preparation
Two vials of anti rabies vaccines received from 
the field were reconstituted with 2.5ml of PBS 
(pH 7.4) each. The reconstituted vaccines from 
the two vials were pooled and kept on ice. A ten 
fold serial dilution of the reconstituted vaccine 
was made in Bijou bottles containing sterile PBS 
-5 (pH 7.4) up to10 dilutions. The same procedure 
was repeated for two vials of vaccines from the 
reference sample.
Mice inoculation
-5Starting from the highest (10  dilution) to the 
-1lowest dilution (10 ), 0.03ml of each dilution 
was inoculated into 8 mice using a 0.5ml 
tuberculin syringe fitted with 27G X ½” needle 
intracerebrally. Eight un-inoculated mice were 
kept alongside to serve as negative control. This 
was also repeated for the reference samples. The 
mice were observed daily for signs of illness, 
paralysis and/or death for 21 days and 
observations recorded. The LD was calculated 50 
using Spearman Karber formula; log LD = X  – 50 o
d/2 + d (? r /n ) where:i i
X  – log  of the reciprocal of the lowest dilution o 10
at which all the test mice died
d – log of the dilution factor (i.e. the difference 10  
between the log dilution intervals)
n  – number of test mice used at each dilution i
(after discarding accidental losses)
r  – number of dead mice (out of n )i i
? r/n – sum of the proportion of positive tests i i
beginning at the lowest dilution showing 
100% mortality (positive result)
RESULTS
Throughout the period of observation, there 
were no sign of illness, paralysis or death in all 
the groups of mice inoculated with the vaccine 
from the field. Death were observed between 
days 7 and 18 post inoculation in the groups 
inoculated with the reference sample of the 
same batch of vaccine, while the controls within 
this group remained healthy throughout the 
period of observation (Fig 1). The summary of 
the observations is as shown in Table I.
TABLE I: Proportion of dead to inoculated mice at the different 
dilutions of the reference compared with the field vaccine
        Reference Sample       Field Sample
Dilution n r P = (r /ni) r     P = (r /n)i i i i i i
110- 8 8 1 0 0
210- 8 8 1 0 0
310- 8 6 0.75 0 0
410- 8 2 0.25 0 0
510- 8 0 0 0 0
n = No. of mice inoculated per dilution, r  = No. of dead mice, i i
P = Proportion of dead to inoculated mice 
Figure 1: Proportion of dead to live mice against days post 
-2inoculation of the reference and the field vaccine at dilution 10
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Calculations
Using the Spearman Karber formula, Log LD  = 50
Xo - d/2 + d ( ri/ni)
Log LD = (-2 -1/2 + 1 (1+0.75+0.25+0)50
= -3.5
Titre = log Ld  3.5/0.03ml of the vaccine50
3.5= 10-  per 0.03ml
?
The OIE recommends vaccine batch with a titre 
-3.3 of 10 per 0.03ml for use but an additional 0.5 
log at production, is required to accommodate 
loss due to storage. The titre of the reference 
-3.5sample of the vaccine 10  is consistent with the 
standard since the vaccine had been in storage 
for almost one year which is the producer's 
recommended shelf life. In this experiment, the 
reference vaccine was viable and potent being 
able to cause death in mice that were inoculated. 
However, the vaccine from the field appears to 
have lost viability and was unable to initiate 
illness, paralysis or death when inoculated 
intracerebrally in mice.
DISCUSSION
Dog rabies has been recognised since the advent 
of human civilization (Wilkinson, 2002), and is 
responsible for a most severe human suffering 
and death. Despite concerted effort at control, 
domestic dogs still pose the greatest public 
health hazard with regards to rabies (Belotto et 
al., 2005) in the developing countries. As 
revealed in this study, biologically viable and 
potent rabies vaccine may lose viability and 
potency due to poor handling and such vaccine is 
ineffective against rabies control and 
management. In countries with canine rabies, 
the disease control/eradication policy has 
always been mass vaccination for the 
elimination of the virus in the major reservoir 
host. In Nigeria, though rabies has been 
responsible for human death and suffering 
(Fagbami et al., 1981), vaccination has been 
poorly implemented with low coverage and 
compliance rates similar to what obtain in most 
developing countries. In developed countries 
like the USA, Canada and Western Europe, urban 
rabies have been successfully controlled with 
strict vaccination policy of domestic dogs and 
cats (WHO, 2005). Available records in the 
Institute's Veterinary Clinic, which serve as the 
main repository for rabies and rabies related 
activities for Nigeria showed that out of a total of 
2,360 dogs suspected of rabies between 1999-
2008, only 171(7.2%) had vaccination records, 
the effectiveness of such vaccination may even 
be doubted in view of the present study. 
According to the WHO, comprehensive control 
measure for rabies must include mass 
vaccination of dogs through campaigns and by 
continuous vaccination of young dogs (WHO, 
2010). 
Controlling rabies has been the mandate of 
governments; vaccination programme for dogs 
generally consisted of periodic visits by a 
government vaccination team on campaigns to 
communities. This may have some effect on 
reducing rabies, when the quality of the vaccine 
can be guaranteed. The current work shows that 
the efficacy of anti-rabies vaccines currently in 
use and their effectiveness in the control of 
rabies should be regularly checked. Rabies is 
preventable by breaking the cycle of 
transmission in dog to dog and man with 
immunogenic vaccines that are not com-
promised by poor handling on the field. 
Reducing the risk of human exposure and safe 
guarding public health is hinged on these 
recommendations.
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